News

Medical cannabis compound alleviates nightmares associated with PTSD

News-Medical.Net Pharmaceutical News - Wed, 2026-08-05 02:50
Nightmares are among the most agonizing symptoms of post-traumatic stress disorder (PTSD) – a condition that can develop after exposure to severe traumatic experiences, such as disasters, serious accidents, acts of violence, or wartime experiences. Individuals affected relive the events intensely at night, as if they were real, time and time again.
Categories: News

Mouse study shows how liraglutide briefly rewires gut bacterial communities

News-Medical.Net Pharmaceutical News - Tue, 2026-08-04 20:28
Researchers treated male high-fat-fed mice with liraglutide for 14 days, then tracked fecal bacterial communities after a 7-day washout using 16S rRNA sequencing. Liraglutide shifted the microbiome toward Lactobacillus- and Leptogranulimonas-related taxa while reducing several fermentative taxa, but most changes moved back toward baseline after treatment stopped.
Categories: News

GLP-1 therapy may help reduce fracture risk among adults with type 2 diabetes

News-Medical.Net Pharmaceutical News - Tue, 2026-08-04 19:08
New research by UCLA Health found GLP-1 medications may reduce the risk of serious fractures for adults with type 2 diabetes.
Categories: News

Tadalafil may increase glaucoma risk in men with enlarged prostates

News-Medical.Net Pharmaceutical News - Tue, 2026-08-04 19:00
An erectile dysfunction drug that is also used to treat symptoms like sudden urgency and frequency, which are associated with an enlarged prostate in men, may heighten the risk of the serious eye condition, glaucoma, finds a large comparative study published online in the British Journal of Ophthalmology.
Categories: News

Food may taste different on GLP-1 drugs, but taste may not be the reason

News-Medical.Net Pharmaceutical News - Mon, 2026-08-03 22:10
The review suggests that patient-reported “taste changes” during GLP-1RA treatment may reflect reduced food enjoyment and motivation rather than consistent impairment of basic taste. The authors propose a sensory-liking-wanting framework while emphasizing that current human evidence remains heterogeneous and largely indirect.
Categories: News

'Me-too' drugs drive increased spending through higher prescribing

News-Medical.Net Pharmaceutical News - Mon, 2026-08-03 13:49
A long-running debate over prescription drug costs has centered on whether drug manufacturers are better rewarded for truly innovative medicines or so-called "me-too" drugs that may offer only incremental improvements over existing treatments but still command high prices.
Categories: News
Syndicate content